m.mwangi

TL2 · Recife

Contributes reviews on supplier material. Based in Recife.

Joined 2 October 2025 · last posted 21h

83Posts here

2Topics

0Solutions

1.2kLikes received

1.9kLikes given

20Badges

237Days visited

4.9kPosts read

Recent activity

Full stream

Journal club: the CagriSema phase 2 combination paper Replied, post #3 · Evidence › Journal club · 27 Jul 2026 · 4 likes TRIUMPH (ongoing): Retatrutide phase 3. No results yet. Nothing should be attributed to it because it has not finished. When it does, this discussion will return to it.…
Lean mass preservation: what the evidence supports — does this still hold? Replied, post #122 · Outcomes › Body composition · 26 Jul 2026 · 5 likes The arithmetic in post #119 is right; the assumption feeding it is the part to check. Preserving lean tissue during a substantial deficit depends on protein intake and…
What a certificate commits its issuer to — the long version Replied, post #24 · Analytics › COA interpretation · 17 Jul 2026 · 8 likes What fields matter on a certificate: lot number matching the vial, test date, the analytical method stated specifically, the measured result as a number, and the…
Follow-up: The most useful thing you learned here that was not the answer you came for Replied, post #27 · Lounge › Off topic · 16 Jul 2026 · 0 likes Non-technical and offered in the right category: the best thing about a forum with no vote score is that the boring accurate answer sits at the same level as the…
Reading a rodent study on a secretagogue without over-extrapolating — the long version Replied, post #37 · Compounds › Secretagogues & GH axis · 13 Jul 2026 · 11 likes On Reading a rodent study, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the…
SURPASS-2 and the comparator dose question that will not go away — what changed since Replied, post #5 · Compounds › Tirzepatide · 12 Jul 2026 · 0 likes SURPASS-2's comparator choice is the criticism that survives. Semaglutide 1.0 mg was the licensed diabetes dose at the time and it was not the highest dose available in…
What is genuinely unknown about long-term amylin agonism Replied, post #2 · Compounds › Cagrilintide & amylin analogues · 4 Jul 2026 · 0 likes The opening post and I disagree about the size of the effect, not about the direction. Research-use-only cagrilintide is not approved for human use and the published…
Asking a follow-up: new topic or new reply? Replied, post #20 · Start Here › How to Ask · 22 Jun 2026 · 0 likes Context that matters: compound, how long in, current dose, relevant history. Context that does not matter: how you feel, your hopes for the outcome, your medical…
A critique that turned out to be unfair, retracted by its author Replied, post #15 · Evidence › Study critique · 19 Jun 2026 · 6 likes The strongest critiques cite the section they rely on. A critique without a page reference is an impression, however well informed. That much is documented. The rest is…
Coming back to: Swirling versus inverting versus leaving it alone Replied, post #21 · Practice › Reconstitution · 15 Jun 2026 · 10 likes The documentation on Swirling versus inverting versus leaving is better than this thread and I say that as someone who has posted in the thread.
About the Shortages category Replied, post #3 · Access › Shortages · 13 Jun 2026 · 0 likes As a member rather than staff: the most useful thing I did when I started reading this category was to work through the tag pages rather than the topic list. The topic…
Follow-up: A parcel that arrived warm: a decision process, not a verdict Replied, post #59 · Practice › Storage & stability · 6 Jun 2026 · 22 likes Everything in post #57 holds. The case it does not cover is the one I have. Clarity is a weak test. A solution can lose a significant fraction of its active content to…